Seven Bridge Financial Group, LLC Xilio Therapeutics, Inc. Transaction History
Seven Bridge Financial Group, LLC
- $478 Million
- Q1 2025
A detailed history of Seven Bridge Financial Group, LLC transactions in Xilio Therapeutics, Inc. stock. As of the latest transaction made, Seven Bridge Financial Group, LLC holds 46,000 shares of XLO stock, worth $31,739. This represents 0.01% of its overall portfolio holdings.
Number of Shares
46,000
Previous 41,000
12.2%
Holding current value
$31,739
Previous $39,000
15.38%
% of portfolio
0.01%
Previous 0.01%
Shares
3 transactions
Others Institutions Holding XLO
# of Institutions
34Shares Held
11.1MCall Options Held
0Put Options Held
0-
Bain Capital Life Sciences Investors, LLC Boston, MA4.57MShares$3.15 Million1.1% of portfolio
-
River Vest Venture Management LLC St. Louis, MO1.44MShares$994,59616.6% of portfolio
-
Morgan Stanley New York, NY1.16MShares$797,5280.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.14MShares$783,6440.0% of portfolio
-
Aju Ib Investment Co., Ltd. Seoul, M5668KShares$460,7410.57% of portfolio
About Xilio Therapeutics, Inc.
- Ticker XLO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 27,471,600
- Market Cap $19M
- Description
- Xilio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients. Its checkpoint inhibitor program includes XTX101, a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1/2 clinical trials in patients with solid tumors. The company also develops cytokine prog...